EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 …

…, N Sattar, DPM Symmons, MT Nurmohamed - Annals of the …, 2017 - ard.bmj.com
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have
increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the …

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

…, Z Szekanecz, N Sattar, MT Nurmohamed - Annals of the …, 2010 - ard.bmj.com
Objectives: To develop evidence-based EULAR recommendations for cardiovascular (CV)
risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and …

[HTML][HTML] Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus

…, HG Raterman, MT Nurmohamed… - Mediators of …, 2010 - hindawi.com
Endothelial dysfunction is regarded as an important factor in the pathogenesis of vascular
disease in obesity-related type 2 diabetes. The imbalance in repair and injury (hyperglycemia, …

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

MT Nurmohamed, HR Buller, E Dekker, DW Hommes… - The Lancet, 1992 - Elsevier
Low-molecular-weight heparins (LMWHs) have theoretical advantages over standard heparin
as postoperative thromboprophylactic agents. We conducted a meta-analysis of studies …

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

GM Bartelds, CLM Krieckaert, MT Nurmohamed… - Jama, 2011 - jamanetwork.com
… Dr Nurmohamed reports having received consultancy fees from Abbott, Roche, Pfizer, MSD,
UCB, BMS, and Wyeth; payment for lectures from Abbott, Roche, and Pfizer; and research …

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

…, CA Wijbrandts, MT Nurmohamed… - Annals of the …, 2007 - ard.bmj.com
Background: A substantial proportion of patients with rheumatoid arthritis (RA) do not respond,
or lose initial response, to adalimumab treatment. One explanation for non-response is …

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

…, E De Groot, MT Nurmohamed… - Arthritis & …, 2006 - Wiley Online Library
Objective Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody against
tumor necrosis factor, may result in the formation of infliximab‐specific IgG antibodies. This …

Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation

…, BAC Dijkmans, MT Nurmohamed - Annals of the …, 2009 - ard.bmj.com
Objectives: Patients with rheumatoid arthritis (RA) have an increased cardiovascular risk, but
the magnitude of this risk is not known precisely. A study was undertaken to investigate the …

Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study

…, BAC Dijkmans, MT Nurmohamed - Arthritis Care & …, 2009 - Wiley Online Library
NurmohamedNurmohamedNurmohamed had full access to all of the data in the
study and takes responsibility for the integrity of the data and the accuracy of the data analysis. …

Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis

…, BA Dijkmans, MT Nurmohamed - Seminars in arthritis and …, 2004 - Elsevier
OBJECTIVE: To evaluate the cardiovascular risk profile of spondylarthropathy patients,
particularly ankylosing spondylitis and psoriatic arthritis. METHODS: A Pubmed literature search …